SAB-176
Influenza
Phase 1Completed
Key Facts
About SAB Biotherapeutics
SAB Biotherapeutics' mission is to leverage its proprietary DiversitAb™ platform to develop a new class of fully human polyclonal antibody therapeutics. Its key achievement is the creation of a validated, scalable production system using transgenic cattle, which has advanced multiple candidates into clinical trials, including a program for COVID-19. The company's strategy is to clinically validate its platform in autoimmune disease, starting with type 1 diabetes, and expand into other areas of high unmet need where polyclonal antibodies offer a differentiated therapeutic profile. As a public company, SAB is focused on executing its clinical milestones to demonstrate proof-of-concept and attract strategic partnerships.
View full company profileTherapeutic Areas
Other Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| PanCytoVir™ (oral probenecid) | TrippBio | IND Submitted |
| Influenza Antibodies | new/era/mabs | Research/Pre-clinical |
| Influenza Countermeasure Program | DynPort Vaccines | Not Specified |
| Influenza Vaccine | Medigen | Preclinical |
| Nasal Influenza Vaccine | Abera Bioscience | Pre-clinical |
| Zapnometinib (ATR-002) | Atriva Therapeutics | Phase 2 |
| EV25 | Eradivir | Pre-clinical |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| Influenza Program | Arisan Therapeutics | Preclinical |
| Universal Influenza Vaccine | Orlance | Pre-IND |
| Enhanced Seasonal Influenza Vaccine | Orlance | Research |
| Baloxavir marboxil (Xofluza®) | Shionogi | Marketed |